Kathy S. Albain

Loyola University Chicago — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

88h-index42.6kcitations500works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(155), HER2/EGFR in Cancer Research(136), Cancer Treatment and Pharmacology(104), Lung Cancer Treatments and Mutations(100), Advanced Breast Cancer Therapies(95)

Publications495 total

Generative AI Enables Breast Cancer Genomic Subtype Prediction from Histology Images
2025Open Access
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women
JAMA Oncology·2025Open Access
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial
UNC Libraries·2025Open Access
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
UNC Libraries·2025Open Access
Abstract RF1-04: Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracycline/Taxane Therapy in High-Risk Early Breast Cancer
Clinical Cancer Research·2025
Abstract P1-09-22: Mechanistic Insight into DAXX-Modulated Sensitivity to Chemotherapy in Triple Negative Breast Cancer
Clinical Cancer Research·2025
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
JCO Precision Oncology·2025· 4 citedOpen Access
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
JNCI Journal of the National Cancer Institute·2024· 8 citedOpen Access
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer
Journal of Clinical Oncology·2024· 8 cited
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
UNC Libraries·2024Open Access
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Nature Medicine·2024· 8 citedOpen Access
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Nature Medicine·2024· 31 citedOpen Access
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival
NEJM Evidence·2024· 12 citedOpen Access
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Journal of Clinical Oncology·2024· 32 citedOpen Access
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
Journal of Clinical Oncology·2024· 12 cited
Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): Survival differences in the context of race, gender and smoking.
Journal of Clinical Oncology·2024
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221
Cancer Chemotherapy and Pharmacology·2024Open Access
Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
Journal of Clinical Oncology·2024· 1 cited
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
Journal of Clinical Oncology·2024· 16 cited
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.
Journal of Clinical Oncology·2024· 1 cited
page 1 of 25Next →

Frequent Co-authors

Kathleen I. Pritchard(8), Joseph M. Unger(8), John J. Crowley(8), Robert B. Livingston(8), Judy C. Boughey(8), Angela DeMichele(8), Daniel F. Hayes(7), David R. Gandara(7), Minetta C. Liu(7), Christina Yau(7), A. Jo Chien(7), Anthony Elias(7), Claudine Isaacs(7), Donald A. Berry(7), Eric P. Winer(6), William C. Wood(6), Gabriel N. Hortobágyi(6), Julie R. Gralow(6), Hope S. Rugo(6), Rita Nanda(6)